For the third consecutive year, the 16 partners of the I3LUNG consortium, an EU-funded project under the Horizon 2020 programme, gather for their annual meeting to share progress and reinforce their position as pioneers in the application of artificial intelligence (AI) in oncology.
I3LUNG represents a disruptive leap forward in the fight against lung cancer. The project has a clear objective: to develop an AI-based tool that empowers oncologists and patients to jointly select the most suitable treatment in a personalized manner.
By integrating clinical and molecular data from lung cancer patients and developing a machine learning algorithm, I3LUNG is building a predictive system that anticipates individual responses to existing therapies. This tool aims thereby to recommend tailored treatments for each patient, shortening decision-making timelines, minimizing the chances of disease progression, and only proposing the necessary exams and analyses while reducing toxicities and adverse effects, all with one key goal: improving patients’ quality of life.
I3LUNG: Innovation with real-world impact
The project is driving transformation across the board:
- For oncologists, it offers a decision-support tool powered by a robust database, with insights that will be made accessible to the wider research community, enhancing and personalizing clinical judgment.
- For patients, it reduces the time between diagnosis and treatment, minimizes side effects, and keeps the focus on recovery. A dedicated patients co-decision tool (IPDAS) is already available in a validated prototype version, with information on the disease, treatment options and their associated survival and quality of life assessments.
- From a health economics perspective, it supports more efficient resource allocation within healthcare systems and reduces costs associated with ineffective or misdirected treatments.
If the algorithm’s effectiveness is confirmed, final results are expected by May 2027, this solution could be extended to other tumor types.
Partners driving change
Launched in June 2022, I3LUNG is one of several projects positioning the consortium as a European leader in AI-driven oncology. Its principal investigator, Dr. Arsela Prelaj, a medical oncologist at the Istituto Nazionale dei Tumori, is spearheading several initiatives stemming from the project, including:
- ESAC (European Society of Artificial Intelligence in Cancer): The first multidisciplinary European society focused on AI in cancer, founded in March 2025 to foster collaboration among oncologists, imaging specialists, scientists, bioinformaticians, and engineers with AI expertise. The Society involves key leaders in the field, representing other EU scientific societies and large research infrastructures – it is presided by Arsela, prof. Jakob Kather as its president-elect, and with our greek partner Helena Linardou as its treasurer.
- Organization of the first European Summer School on AI for Oncology hosted by I3LUNG partner Metropolitan Hospital of Athens: a training program that brings together young researchers and international experts to accelerate knowledge transfer and cultivate the next generation of AI leaders in oncology. Several I3LUNG partners compose the faculty of this event, the first under ESAC’s umbrella (H. Linardou, A. Prelaj, S. Kosta, M. Garassino, A. Pearson, M. Reck, E. Felip).
With its first actionable results achieved, I3LUNG has reached out to other EU initiatives in the oncology AI area – and the new steps in the broader data sharing framework in Europe (EHDS): SHAIPED, EUCAIM, and more. This year, Dr. Prelaj has also been invited as a keynote speaker at the World Conference on Lung Cancer (WCLC), one of the world’s foremost events in lung cancer. Alongside other consortium members, she will participate in the inaugural edition of ESMO AI, a new congress organized by the European Society for Medical Oncology, taking place in October in Berlin, focused entirely on AI’s clinical, research, and regulatory applications in oncology.
I3LUNG is moving steadily from theory to practice, laying the foundations for a future in which artificial intelligence becomes a key ally in enhancing clinical decision-making, personalized medicine, while empowering patients in the management of their disease. In conclusion, I3LUNG stands out as one of Europe’s most ambitious and inspiring projects at the intersection of science, technology and health.
CONSUMER – Hacia una enfermedad prevenible, curable o crónica.
Bio World – A $10M EU initiative launches to develop AI-based personalized medical care for lung cancer patients.
Milano Today – A Milano l’intelligenza artificiale per curare il tumore ai polmoni.
Il Giorno – Big data contro il cancro al polmone Così l’Int studia cure personalizzate.
Ordine Nazionale Biologi – Tumore al polmone: progetto UE per le cure basate sull’Intelligenza Artificiale.
Teknoscienze – LAUNCH OF I3LUNG: A HORIZON EUROPE PROJECT TO IMPLEMENT PERSONALISED MEDICAL CARE BASED ON ARTIFICIAL INTELLIGENCE (AI) IN LUNG CANCER PATIENTS.
About pharma – Tumore al polmone, al via il progetto I3LUNG per terapie personalizzate basate sull’Ai.
Notiziario Chimico Farmaceutico – I3Lung, al via il progetto per l’uso dell’AI nel campo del tumore ai polmoni.
Tecnica Ospedaliera – I3LUNG, cure basate su intelligenza artificiale contro il tumore al polmone.
Sky TG24 – Tumore al polmone, un progetto europeo per le cure basate sull’Intelligenza Artificiale.
Il Sole 24 Ore – I3LUNG, l’IA per ottimizzare le terapie oncologiche.
IM Médico Hospitalario – MEDSIR apuesta por la medicina personalizada ante el cáncer de pulmón.
Ask a News – Intelligenza Artificiale e Salute: un binomio vincente.
Sky TG24 – Tumore al polmone, un progetto europeo per le cure basate sull’Intelligenza Artificiale.
Protothema Το Metropolitan Hospital εταίρος στην κοινοπραξία I3LUNG.
Iefimerida – To Metropolitan Hospital εταίρος στην κοινοπραξία I3LUNG.
Mississippi Oncology Society – MEDSIR participates in a project of the Horizon Europe Program for the creation of a personalized medicine platform in lung cancer.
Society of Utah Medical Oncologists – MEDSIR participates in a project of the Horizon Europe Program for the creation of a personalized medicine platform in lung cancer.
Alabama Cancer Congress – MEDSIR participates in a project of the Horizon Europe Program for the creation of a personalized medicine platform in lung cancer.
Medical Oncology Association of California – MEDSIR participates in a project of the Horizon Europe Program for the creation of a personalized medicine platform in lung cancer.
Journal of Commercial Biotechnology – MEDSIR participates in a project of the Horizon Europe Program for the creation of a personalized medicine platform in lung cancer.
Biotech Blog – MEDSIR participates in a project of the Horizon Europe Program for the creation of a personalized medicine platform in lung cancer.
Bio NJ – MEDSIR participates in a project of the Horizon Europe Program for the creation of a personalized medicine platform in lung cancer.
Drug Patent Watch – MEDSIR participates in a project of the Horizon Europe Program for the creation of a personalized medicine platform in lung cancer.
Morning Star – MEDSIR participates in a project of the Horizon Europe Program for the creation of a personalized medicine platform in lung cancer.
FOX 8 – MEDSIR participates in a project of the Horizon Europe Program for the creation of a personalized medicine platform in lung cancer.
PRNewswire – MEDSIR participates in a project of the Horizon Europe Program for the creation of a personalized medicine platform in lung cancer.
National Oncology State network – MEDSIR participates in a project of the Horizon Europe Program for the creation of a personalized medicine platform in lung cancer.
PRNewswire – MEDSIR prend part à un projet du programme Horizon Europe visant la création d’une plateforme de médecine personnalisée contre le cancer du poumon.
Lang1234 – MEDSIR prend part à un projet du programme Horizon Europe visant la création d’une plateforme de médecine personnalisée contre le cancer du poumon.
Notre siècle – MEDSIR prend part à un projet du programme Horizon Europe visant la création d’une plateforme de médecine personnalisée contre le cancer du poumon.
Nos médicaments – MEDSIR prend part à un projet du programme Horizon Europe visant la création d’une plateforme de médecine personnalisée contre le cancer du poumon.
Redacción Médica – Ok’ de Europa al proyecto I3LUNG que mejora la terapia de cáncer de pulmón.
Siglo XXI – La Comisión Europea da luz verde a la creación de una plataforma de medicina personalizada en cáncer de pulmón.
El Economista – Medsir se suma a un proyecto europeo de cáncer de pulmón financiado con 10 millones.
Infosalus – La Comisión Europea da luz verde a la creación de una plataforma de medicina personalizada en cáncer de pulmón.
Noticiasde.es – La Comisión Europea da luz verde a la creación de una plataforma de medicina personalizada en cáncer de pulmón.
News Tercera Edad – MEDSIR participa en un proyecto del programa Horizonte Europa para la creación de una plataforma de medicina personalizada en cáncer de pulmón.
VHIO – VHIO takes part in I3LUNG: An EU-funded Project fostering the implementation of artificial intelligence (AI)-based personalized medical care for lung cancer patients.
Colombia ES Euro News – Proyecto I3LUNG, plataforma sobre terapia del cáncer de pulmón.
Con Salud – Luz verde a la plataforma europea de medicina personalizada en cáncer de pulmón.
Isanidad – Europa aprueba la creación de una plataforma de medicina personalizada en cáncer de pulmón financiada con 10 millones.
Planta Doce – MEDSIR se apoya en Horizonte Europa para crear una plataforma sobre cáncer de pulmón.